A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.

Ravi Vij,Nikoletta Lendvai,Thomas G. Martin,Rachid Baz,Frank Campana,Florent Mazuir,Éric Charpentier,Don M. Benson

A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.

2016

Ravi Vij
Nikoletta Lendvai
Thomas G. Martin
Rachid Baz
Frank Campana
Florent Mazuir
Éric Charpentier
Don M. Benson

8009Background: Isatuximab (ISA), a humanized anti-CD38 monoclonal antibody, has demonstrated activity in patients (pts) with RRMM in combination with Len/Dex in an ongoing Phase 1b study (NCT01749...

Keywords:

Dexamethasone
Oncology
Pathology
Lenalidomide
Interim
Isatuximab
CD38
Refractory Multiple Myeloma
Internal medicine
Monoclonal antibody
Medicine
Multiple myeloma
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations